Comprehensive analysis of the regional dynamics shaping the market; and Exhaustive assessment of the key market players and their dominant strategies. Hemophilia is a rare bleeding disorder that is ...
RARITAN, N.J., July 2, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today results of an open label, single-center, parallel group study showing that a type of ...
PARAMUS, N.J., July 26, 2023 – Octapharma USA today announced that Balfaxar ® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex ®) has received U.S. Food and Drug ...
The 94.3% efficacy of the Octapharma product was just a shade ahead of the 94.2% measured in a comparative product, Kcentra. Results of a Phase III study (LEX-209) of the safety and efficacy of ...
Approximately 15% of patients undergoing cardiac surgery experience excessive bleeding that leads to depletion of clotting factors. Transfusion of frozen plasma is the standard treatment for excessive ...
Among over 300 patients with the highest trauma level activation, the absolute difference in median total 24-hour blood product consumption between the 4F-PCC and placebo groups was 0.2 U (95% CI ...
For patients who experience excessive bleeding during cardiac surgery, four-factor prothrombin complex concentrate (4F-PCC), a blood product that contains clotting factors, is significantly more ...
Treatment with four-factor prothrombin complex concentrate was superior to plasma for the urgent reversal of vitamin K antagonist-induced anticoagulation prior to surgery, according to phase 3b study ...
TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback